Our actions and results continue to demonstrate an unyielding commitment to deliver the most in terms of shareholder value. We took strategic risks -- and now -- as we look ahead -- we see the reward of significantly enhanced long-term growth prospects for an even brighter future for Mylan and its shareholders. Following our exceptional earnings performance in 2008, our reaffirmed adjusted EPS projections reflect strong earnings growth of approximately 25% from 2008 to 2009, and an even stronger earnings growth rate of approximately 60% from 2009 to 2010."
Total revenues for the quarter ended Dec. 31, 2008, increased by $47.8 million or 4% to $1.20 billion from $1.16 billion in the same prior year period. This increase includes the unfavorable impact from the stronger U.S. dollar, which reduced sales by approximately 6%. Excluding the effect of the stronger U.S. dollar, year-over-year revenue growth was approximately 10%.
Generics revenues, which are derived from sales in North America, Europe, the Middle East & Africa (collectively, "EMEA") and Asia Pacific, were $1.03 billion in the current quarter compared to $960.9 million in the same prior year period.
Total revenues from North America were $556.2 million for the three months ended Dec. 31, 2008 compared to $416.9 million for the same prior year period, representing an increase of $139.3 million. Higher sales from new product launches in the United States, as well as higher sales of Mylan's Fentanyl Transdermal System ("fentanyl"), Mylan's AB-rated generic alternative to Duragesic(R), are primarily responsible for the increase in revenues. Higher volume offset by unfavorable pricing as a result of additional generic competition on certain products, was also realized throughout the company's portfolio.
In the current quarter, new products launched in the United States contributed revenues ofPage: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Related biology technology :1
. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 20152
. Mylan to Host Investor Day on October 3, 20073
. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD4
. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations5
. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets6
. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules7
. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement8
. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets9
. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States10
. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)11
. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008